PMID- 20354454
OWN - NLM
STAT- MEDLINE
DCOM- 20100812
LR  - 20211130
IS  - 1556-1380 (Electronic)
IS  - 1556-0864 (Linking)
VI  - 5
IP  - 5
DP  - 2010 May
TI  - CD24, a novel cancer biomarker, predicting disease-free survival of non-small 
      cell lung carcinomas: a retrospective study of prognostic factor analysis from 
      the viewpoint of forthcoming (seventh) new TNM classification.
PG  - 649-57
LID - 10.1097/JTO.0b013e3181d5e554 [doi]
AB  - INTRODUCTION: Metastasis-associated protein CD24 has been identified as a new 
      prognostic factor and stem cell marker in the human neoplasm. However, the 
      importance of the CD24 in non-small cell lung carcinomas (NSCLCs) has not been 
      elucidated well. METHODS: We evaluated CD24 expression in 267 consecutive cases 
      of NSCLC by immunohistochemistry using a tissue microarray technique and 
      correlated with clinicopathologic parameters including forthcoming (seventh) new 
      tumor node metastasis classification. RESULTS: CD24-high expression was 
      demonstrated in 87 of 267 (33%) and was associated with adenocarcinoma (ADC) 
      histology than in squamous cell carcinoma histology (64 of 165 [39%] vs. 20 of 88 
      [23%]; p = 0.023). Patients with CD24-high tumors tended to have a higher risk of 
      disease progression (p < 0.001) and cancer-related death (p = 0.002). 
      Multivariate analysis proved CD24-high expression as independent prognostic 
      factors of disease progression and cancer-related death (p = 0.002, hazard ratio 
      = 1.78, 95% confidence interval = 1.23-2.58 and p = 0.017, hazard ratio = 1.93, 
      95% confidence interval =1.13-3.31). CD24-high expression had a tendency to 
      correlate with new pathologic stage (p-stage) (p = 0.089) rather than old p-stage 
      (p = 0.253). Performance status and new p-stage, regardless of the tumor 
      histology, were identified as consistent independent prognostic factors of 
      disease progression and cancer-related death. However, age was related to a 
      significantly shorter cancer-specific survival in ADC only. CONCLUSIONS: CD24 
      expression in NSCLC is associated with ADC histology and disease progression and 
      cancer-related death, indicative of aggressive tumor behavior. Performance status 
      and new p-stage, to a lesser extent, age correlated with progression-free 
      survival and cancer-specific survival, regardless of tumor histology.
FAU - Lee, Hyun Ju
AU  - Lee HJ
AD  - Department of Pathology, Seoul National University College of Medicine, Bundang 
      Hospital and Tumor Immunity Medical Research Center, Seoul National University 
      College of Medicine, 300 Gumidong, Bundang-gu, Seongnam city, Gyeonggi-do 
      463-707, Republic of Korea.
FAU - Choe, Gheeyoung
AU  - Choe G
FAU - Jheon, Sanghoon
AU  - Jheon S
FAU - Sung, Sook-Whan
AU  - Sung SW
FAU - Lee, Choon-Taek
AU  - Lee CT
FAU - Chung, Jin-Haeng
AU  - Chung JH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Thorac Oncol
JT  - Journal of thoracic oncology : official publication of the International 
      Association for the Study of Lung Cancer
JID - 101274235
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD24 Antigen)
RN  - 0 (CD24 protein, human)
SB  - IM
CIN - Biomark Med. 2010 Aug;4(4):495. PMID: 20701438
MH  - Adenocarcinoma/classification/*metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*metabolism
MH  - CD24 Antigen/*metabolism
MH  - Carcinoma, Non-Small-Cell Lung/classification/*metabolism/pathology
MH  - Carcinoma, Squamous Cell/classification/*metabolism/pathology
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Lung Neoplasms/classification/*metabolism/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Young Adult
EDAT- 2010/04/01 06:00
MHDA- 2010/08/13 06:00
CRDT- 2010/04/01 06:00
PHST- 2010/04/01 06:00 [entrez]
PHST- 2010/04/01 06:00 [pubmed]
PHST- 2010/08/13 06:00 [medline]
AID - S1556-0864(15)32138-9 [pii]
AID - 10.1097/JTO.0b013e3181d5e554 [doi]
PST - ppublish
SO  - J Thorac Oncol. 2010 May;5(5):649-57. doi: 10.1097/JTO.0b013e3181d5e554.